Rogers remet 1 million de dollars à la grande gagnante de Canada’s Got Talent : REBECCA STRONG de PRINCE ALBERT, en SASKATCHEWAN
May 14, 2024 23:48 ET
|
Rogers Communications Canada Inc.
– REBECCA STRONG reçoit 1 million de dollars de Rogers, le plus gros prix en argent de l’histoire télévisuelle canadienne, en plus de conseils financiers de la CIBC, pour l’aider à concrétiser ses...
Forsys Reports Updated Mineral Resource Estimate for its Norasa Project in Namibia
May 14, 2024 07:00 ET
|
Forsys Metals Corp
TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Forsys Metals Corp. (TSX: FSY) (FSE: F2T) (NSX: FSY) (“Forsys” or the “Company”) Forsys is pleased to provide an update for the...
Stabilization Notice - ILIAD EUR TAP
May 13, 2024 04:15 ET
|
BNP Paribas Primary New Issues
13th May 2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ILIAD HOLDING S.A.S. ...
Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
May 10, 2024 06:00 ET
|
Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of...
Thérapeutique Knight déclare ses résultats du premier trimestre de 2024
May 09, 2024 07:30 ET
|
Thérapeutique Knight inc.
MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), une société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.) de...
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
May 08, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through...
Global Indexable Inserts Market Report 2024-2029: Technology and Market Overview, PCD Diamond Inserts, cBN/PcBN Inserts, Ceramic Inserts, Carbide Inserts
May 08, 2024 04:00 ET
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Indexable Inserts - Global Markets, End-Users, Applications & Competition 2024-2029" report from Dedalus Consulting has been added to ...
Ocular Therapeutix™ Reports First Quarter 2024 Results
May 07, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2024 20:16 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the...